SRL
INTS icon

Scientech Research LLC’s Intensity Therapeutics INTS Stock Holding History

Scientech Research LLC’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-989
Closed -$6K – 643
2025
Q3 		$6K Buy
+989
New +$7.07K ﹤0.01% 548

Other funds holding INTS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
LA
Legacy Advisors Plymouth Meeting, Pennsylvania $1.07B AUM 26.49% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Scientech Research LLC's INTS Position: Q4 2025 in Review

Scientech Research LLC sold out of Intensity Therapeutics (INTS) in Q4 2025, closing a stake of 989 shares — an estimated $6K sold.

Scientech Research LLC first reported a position in INTS in Q3 2025 and held it in 1 quarter. The position peaked at $6K in Q3 2025. 35 funds tracked by Wall St. Rank hold INTS as of Q4 2025.

  • Scientech Research LLC reported no remaining Intensity Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Scientech Research LLC sold 989 Intensity Therapeutics shares in Q4 2025, an estimated $6K.
  • Scientech Research LLC first reported a position in Intensity Therapeutics in Q3 2025 and held it in 1 quarter.
  • Scientech Research LLC's Intensity Therapeutics position peaked at $6K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q4 2025.

Based on Scientech Research LLC's 13F filing for Q4 2025, filed 17 Feb 2026.